Can you take Asparaginase escherichia coli with Children's ElixSure?

The acetaminophen in Children's ElixSure has a major potential interaction with Alcoholism.

Chronic alcohol abusers may be at increased risk of hepatotoxicity during treatment with acetaminophen (APAP). Severe liver injury, including cases of acute liver failure resulting in liver transplant and death, has been reported in patients using acetaminophen. Therapy with acetaminophen should be administered cautiously, if at all, in patients who consume three or more alcoholic drinks a day. In general, patients should avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure. They should also be advised to seek medical attention if they experience signs and symptoms of liver injury such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice.

asparaginase Escherichia coli has a major potential interaction with Bleeding Disorder.

Impaired synthesis of fibrinogen and decreased serum levels of clotting factors have been reported in patients in asparaginase therapy. Bleeding has been observed in patients with coagulation disorders. Patients should be instructed to immediately report any signs or symptoms suggesting bleeding such as petechiae, purpura, hematuria, or melena. Therapy with asparaginase should be administered cautiously to patients with coagulation disorders. The use of asparaginase is contraindicated in patients with serious bleeding or history of serious hemorrhagic events with prior to asparaginase therapy.

asparaginase Escherichia coli has a moderate potential interaction with Bone Marrow Depression/Low Blood Counts.

Transient myelosuppression has been observed during asparaginase therapy, however its myelosuppressive effect has not been well characterized. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitoring of hematopoietic function is recommended. Therapy with asparaginase should be administered cautiously in patients with severe bone marrow suppression.

asparaginase Escherichia coli has a major potential interaction with Coagulation Defects and Disorders.

Impaired synthesis of fibrinogen and decreased serum levels of clotting factors have been reported in patients in asparaginase therapy. Bleeding has been observed in patients with coagulation disorders. Patients should be instructed to immediately report any signs or symptoms suggesting bleeding such as petechiae, purpura, hematuria, or melena. Therapy with asparaginase should be administered cautiously to patients with coagulation disorders. The use of asparaginase is contraindicated in patients with serious bleeding or history of serious hemorrhagic events with prior to asparaginase therapy.

The acetaminophen in Children's ElixSure has a major potential interaction with Dehydration.

Acetaminophen is contraindicated in patients with severe hepatic impairment or severe active liver disease. Patients with hepatic impairment may be at increased risk of toxicity. Severe liver injury, including cases of acute liver failure and death, have been reported in patients using this drug. Clinical monitoring of hepatic function is recommended. Caution is advised if using acetaminophen in patients with chronic malnutrition or severe hypovolemia. Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.

asparaginase Escherichia coli has a moderate potential interaction with Diabetes Mellitus.

Glucose intolerance has been reported in patients receiving asparaginase. In some cases glucose intolerance may be irreversible. Monitor glucose levels in patients at baseline and periodically during treatment. Administer insulin therapy as necessary in patients with hyperglycemia. Therapy with asparaginase should be administered cautiously in patients with diabetes mellitus.

The acetaminophen in Children's ElixSure has a major potential interaction with Liver Disease.

Acetaminophen is contraindicated in patients with severe hepatic impairment or severe active liver disease. Patients with hepatic impairment may be at increased risk of toxicity. Severe liver injury, including cases of acute liver failure and death, have been reported in patients using this drug. Clinical monitoring of hepatic function is recommended. Caution is advised if using acetaminophen in patients with chronic malnutrition or severe hypovolemia. Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.

asparaginase Escherichia coli has a moderate potential interaction with Liver Disease.

Reversible liver abnormalities such as elevated liver transaminase and bilirubin levels and decreased albumin synthesis have been reported during asparaginase therapy. Fatty changes in the liver have been noted. Patients should be instructed to immediately report any sign or symptoms of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia. Therapy with asparaginase should be administered cautiously to patients with or predisposed to compromised hepatic function. Clinical monitoring of hepatic function is recommended.

The acetaminophen in Children's ElixSure has a major potential interaction with Malnourishment.

Acetaminophen is contraindicated in patients with severe hepatic impairment or severe active liver disease. Patients with hepatic impairment may be at increased risk of toxicity. Severe liver injury, including cases of acute liver failure and death, have been reported in patients using this drug. Clinical monitoring of hepatic function is recommended. Caution is advised if using acetaminophen in patients with chronic malnutrition or severe hypovolemia. Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.

asparaginase Escherichia coli has a major potential interaction with Pancreatitis.

The use of asparaginase is contraindicated in patients with pancreatitis or a history of pancreatitis. Pegaspargase can cause decreased insulin synthesis or may cause inflammation and/or necrosis of cells of the pancreas. Fulminant and fatal pancreatitis has occurred. Clinical monitoring of pancreatic function, including serum amylase levels, is recommended.

The acetaminophen in Children's ElixSure has a moderate potential interaction with Phenylketonuria.

Several oral acetaminophen and acetaminophen-combination products, particularly flavored chewable tablets, contain the artificial sweetener, aspartame (NutraSweet). Aspartame is converted to phenylalanine in the gastrointestinal tract following ingestion. Chewable and effervescent formulations of acetaminophen products may also contain phenylalanine. The aspartame/phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).

asparaginase Escherichia coli has a minor potential interaction with Psychosis.

Reversible CNS symptoms, varying from mild to severe, such as depression, confusion, agitation, or hallucinations have been reported. Patients with existing or predisposition to psychoses or emotional disorders may be at increase risk for CNS symptoms associated with asparaginase therapy. Clinical monitoring of mental status is recommended.